regulatory
confidence high
sentiment positive
materiality 0.60
ADMA Biologics receives FDA approval for ninth plasma collection center in Dallas, GA
ADMA BIOLOGICS, INC.
- FDA approved Dallas, GA facility's BLA; center began plasma collection in Q3 2022.
- Facility now licensed to collect and ship source plasma interstate for manufacturing.
- Company on track to have all 10 centers FDA-licensed by year-end 2023.
- Supports plasma self-sufficiency, revenue growth, and profitability outlook.
- Facility features Haemonetics NexSys Persona system; expects staff of 50 at capacity.